Medication info
Pigzone Tablets (Pioglitazone Hydrochloride)

Pigzone Tablets (Pioglitazone Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Samnam Pharmaceutical Co., Ltd.
Appearance
White to grayish-white, round, and convex tablets
Packaging
30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200703601 · Notified 2007.03.28 · Insurance code 653701370

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
This drug is administered orally once daily, regardless of meals. Clinically, if glycemic control does not worsen in patients with diabetes, this drug should be administered for an appropriate period (at least 3 months) to assess changes in glycated hemoglobin. 1. Monotherapy In patients whose blood glucose is not adequately controlled by diet and exercise, this drug may be initiated as monotherapy with pioglitazone 15 mg once daily. If the initial dose of this drug does not provide sufficient efficacy, the dose may be increased to 30 mg once daily. 2. Combination therapy 1) Sulfonylurea: This drug may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this drug, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This drug may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this drug, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this drug. 3) Insulin: This drug may be administered in combination with insulin; the dose is 15 mg once daily. The current insulin dose may be maintained when combination therapy with this drug is initiated. However, if a patient receiving this drug in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended.
Child dose
Use is not recommended in children under 18 years of age because there is no experience with use in this age group.

Ingredients

Manufacturer
Samnam Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Blood sugar control issues in patients with Type 2 Diabetes
View approved original text

This medication is used to improve blood sugar control in patients with Type 2 Diabetes. It can be administered alone as an adjunct to dietary and exercise regimens, and can also be combined with sulfonylureas, metformin, or insulin if other oral hypoglycemic agents have not been effective. Additionally, it is important for patients with Type 2 Diabetes to engage in dietary counseling, weight loss, and regular exercise to enhance therapeutic effects. This integrated treatment approach aids in improving blood sugar control and managing diabetes.

How to take

Adult dose

This drug is administered orally once daily, regardless of meals. Clinically, if glycemic control does not worsen in patients with diabetes, this drug should be administered for an appropriate period (at least 3 months) to assess changes in glycated hemoglobin. 1. Monotherapy In patients whose blood glucose is not adequately controlled by diet and exercise, this drug may be initiated as monotherapy with pioglitazone 15 mg once daily. If the initial dose of this drug does not provide sufficient efficacy, the dose may be increased to 30 mg once daily. 2. Combination therapy 1) Sulfonylurea: This drug may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this drug, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This drug may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this drug, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this drug. 3) Insulin: This drug may be administered in combination with insulin; the dose is 15 mg once daily. The current insulin dose may be maintained when combination therapy with this drug is initiated. However, if a patient receiving this drug in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended.

Child dose

Use is not recommended in children under 18 years of age because there is no experience with use in this age group.

Precautions

This medication is used for the treatment of Type 2 Diabetes and helps improve insulin sensitivity to control blood sugar. However, it may affect heart function, so it should not be administered to patients with heart failure or a history of heart failure. During treatment, patients need to be closely monitored for symptoms of heart failure such as weight changes, dyspnea, and edema; if any of these symptoms occur, consultation with a physician should be sought immediately. Patients with active bladder cancer or a history of bladder cancer should not use this medication, and any occurrence of hematuria or urination difficulties during treatment should be reported to healthcare personnel immediately. Caution is also necessary for patients with impaired liver function or severe kidney disease. Furthermore, the risk of hypoglycemia may increase when this medication is used with insulin, so patients should be familiar with symptoms of hypoglycemia and may need adjustments in the dosage of concomitant medications. Women who are premenopausal may experience increased chances of ovulation due to this medication, so it is advisable to employ adequate contraceptive methods. Regular monitoring of blood sugar and liver function tests during treatment is essential, and patients should inform their physicians immediately if they experience sudden weight gain, edema, or shortness of breath. Elderly patients or those taking other oral hypoglycemic agents, as well as patients with heart conditions or renal dysfunction, should use this medication with particular caution. Lastly, it is safe not to administer this medication to pregnant women, women who may become pregnant, or breastfeeding mothers, and children under 18 years of age.

Side effects

  • Congestive heart failure
  • excessive and rapid weight changes
  • shortness of breath
  • edema
  • fluid retention
  • edema
  • upper respiratory tract infection
  • headache
  • sinusitis
  • myalgia
Show 57 more
  • pharyngitis
  • abdominal distension
  • weight gain
  • hypoglycemia
  • urinary tract infection
  • low back pain
  • dizziness
  • elevated serum creatine kinase
  • hypertension
  • heart failure
  • limb pain
  • chest pain
  • elevated serum ALT levels
  • liver failure
  • decreased vision
  • diabetic macular edema
  • increased blood sugar
  • loss of appetite
  • constipation
  • upper abdominal pain
  • chest pain
  • fatigue
  • weakness
  • indigestion
  • nausea
  • shortness of breath
  • itching
  • chest discomfort
  • trembling
  • chills
  • gastrointestinal disease
  • abdominal pain
  • epigastric discomfort
  • numbness
  • muscle rigidity
  • head discomfort
  • increased liver enzymes
  • worsening liver disease
  • urticaria
  • eczema
  • joint pain
  • knee abnormalities
  • arm weakness syndrome
  • proteinuria
  • increased serum creatinine
  • anxiety
  • insomnia
  • drowsiness
  • simple herpes
  • blurred vision
  • orthostatic hypotension
  • palpitations
  • stroke
  • sexual dysfunction
  • myocardial infarction
  • heart failure
  • fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a container that blocks light and air, and care should be taken to avoid moisture. It is best to store it at a temperature between 15 and 30 degrees Celsius, especially at room temperature around 25 degrees Celsius.

Appearance and packaging

Appearance

White to grayish-white, round, and convex tablets

Package unit

30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.